anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The purpose of this study was to evaluate the efficacy and clinical value of US, FNAC,FNA-Tg and FNAC + FNA-Tg, as well as the cutoff values of FNA-Tg to evaluate LN metastasis.
METHODS: We analyzed the diagnostic value of different US signs, the efficiency of US, FNAC, FNA-Tg and FNAC + FNA-Tg among the LN- and LN + groups, and the cutoff value of FNA-Tg to evaluate LN metastasis. We punctured LNs multiple times and measured the levels of FNA-Tg. Furthermore, the LNs were marked with immunohistochemical Tg and LCA to distinguish the presence of Tg in the para-cancerous tissue of the LNs.
RESULTS: The s-Tg and FNA-Tg of the LN + group were higher than those of the LN- group (P = 0.018, ≤ 0.001). The LN + group had more abnormal US signs than the LN- group. The cutoff value of FNA-Tg was 3.2 ng/mL. US had a high sensitivity (92.42), but the specificity was not satisfactory (55.1). FNA-Tg had a higher sensitivity (92.42 vs. 89.39), specificity (100 vs. 93.88), and accuracy (92.42 vs. 83.27) than FNAC. However, the sensitivity of FNAC + FNA-Tg increased further, while the specificity and accuracy decreased slightly. The presence of Tg in the normal lymphocytes adjacent to the cancer was confirmed.
CONCLUSION: Ultrasonography provides a noninvasive, dynamic, multidimensional assessment of LNs. With a cutoff value of 3.2 ng/mL, FNA-Tg has higher accuracy and a lower false-negative rate than various single diagnoses. However, FNAC combined with FNA-Tg does not cause additional pain to patients and offers a higher diagnostic efficacy and clinical value.
Safety and efficacy of VANOS Cream in pediatric patients younger than 12 years of age have not been established; therefore use in pediatric patients younger than 12 years of age is not recommended.

HPA-axis suppression was studied in 4 sequential cohorts of pediatric patients with atopic dermatitis covering at least 20% of the body surface area, treated once daily or twice daily with VANOS Cream. The first cohort of 31 patients (mean 36.3% BSA) 12 to < 18 years old; the second cohort included 31 patients (mean 39.0% BSA) 6 to < 12 years old; the third cohort included 30 patients (mean 34.6% BSA) 2 to < 6 years old; the fourth cohort included 31 patients (mean 40.0% BSA) 3 months to < 2 years old. VANOS Cream caused HPA-axis suppression in 1 patient in the twice daily group in Cohort 1, 2 patients in the twice daily group in Cohort 2, and 1 patient in the twice daily group in Cohort 3. Follow-up testing 14 days after treatment discontinuation, available for all 4 suppressed patients, demonstrated a normally responsive HPA-axis. Signs of skin atrophy were present at baseline and severity was not determined making it difficult to assess local skin safety. Therefore, the safety of VANOS Cream in patients younger than 12 years of age has not been demonstrated.

Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA-axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children.

HPA-axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to cosyntropin (ACTH1–24) stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
The invention discloses a rapid disintegrant preparation composition of bismuth subsalicylate and a preparing method thereof. Rapid disintegrant preparations comprise a dispersing tablet, an oral cavity disintegration tablet, and an effervescent tablet. The active component bismuth subsalicylate is an insoluble salt formed by trivalent bismuth and salicylate. In order to reduce the gritty sense and discomfort of the bismuth subsalicylate in the oral cavity, the bismuth subsalicylate is micronized, with the particle size being controlled within a range of 50-150 [mu]m. The disintegrant in the rapid disintegrant preparation is one or more selected from crosslinked polyvinylpyrrolidone, low-substituted hydroxy propyl cellulose, crosslinked sodium carboxymethylcellulose and sodium carboxymethyl starch, or is used with an effervescent disintegrant in combination. The effervescent disintegrant can accelerate the disintegration speed, and the taste like soda water of the effervescent disintegrant can cover the gritty sense and discomfort brought by the insoluble main medicine. Sodium dodecyl sulfate, a wetting agent, is also added in to the composition so as to accelerate the disintegration. The composition is convenient to take, increases the compliance of patients and can achieve a function of taking effect rapidly.
HRVB as indicated in Arm 2. No instruction will be provided for cough suppression, laryngeal desensitization, voice tasks or hygiene that traditionally reduces cough frequency and severity. This is the experimental arm.
The present invention pertains to methods of characterizing the effects on the skin of skin-molding agents and to methods of characterizing the physical behavior of the skin-molding agents themselves. A preferred embodiment of the present invention uses a non-invasive, in vivo form of digital image speckle correlation to track deformation of human skin caused by the application of a skin-molding agent, in particular, an immediate-effect skin molding agent. The skin-molding agent may or may not be part of a composition. The application to the skin of a skin-molding agent may or may not be part of a treatment regimen. The present invention may be applied to any surface of the human body, to non-humans and to inert matter. Unlike in vitro methods and unlike invasive, in vivo methods that tension the skin with an apparatus, the present invention relies on the applied skin-molding agent to create before and after deformation images. From those images, it is possible to develop quantitative and qualitative characterizations of skin's movement and of the skin-molding agent itself. These characterizations will aid in the development of improved and/or customized skin molding agents and improved compositions comprising skin-molding agents. Generally, the data collected by the methods described herein, may also suggest improved and/or customized treatment regimens for molding the skin.
Because of reports of thrombocytopenia (see WARNINGS), inhibition of the secondary phase of platelet aggregation, and abnormal coagulation parameters, (e.g., low fibrinogen), platelet counts and coagulation tests are recommended before initiating therapy and at periodic intervals. It is recommended that patients receiving Divalproex Sodium Delayed-Release Tablets, USP be monitored for platelet count and coagulation parameters prior to planned surgery. In a clinical trial of divalproex sodium as monotherapy in patients with epilepsy, 34/126 patients (27%) receiving approximately 50 mg/kg/day on average, had at least one value of platelets ≤75 x 109/L. Approximately half of these patients had treatment discontinued, with return of platelet counts to normal. In the remaining patients, platelet counts normalized with continued treatment. In this study, the probability of thrombocytopenia appeared to increase significantly at total valproate concentrations of ≥110 µg/mL (females) or ≥135 µg/mL (males). Evidence of hemorrhage, bruising, or a disorder of hemostasis/coagulation is an indication for reduction of the dosage or withdrawal of therapy.

Since divalproex sodium may interact with concurrently administered drugs which are capable of enzyme induction, periodic plasma concentration determinations of valproate and concomitant drugs are recommended during the early course of therapy. (See PRECAUTIONS - Drug Interactions.)

Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test.

There have been reports of altered thyroid function tests associated with valproate. The clinical significance of these is unknown.

Suicidal ideation may be a manifestation of certain psychiatric disorders, and may persist until significant remission of symptoms occurs. Close supervision of high risk patients should accompany initial drug therapy.

There are in vitro studies that suggest valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions. The clinical consequence, if any, is not known. Additionally, the relevance of these in vitro findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. Nevertheless, these data should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.
BACKGROUND: The blunt injuries may be heterogeneous. Due to the diversity, it is often difficult to establish the type of weapon used. Particular attention must be paid to the circumstantial data and previous diseases because the injuries often could not correspond to the presumed instruments used.
CASE REPORT: A man was found dead in his bedroom wearing pajamas. On the bed there was a blanket with visible traces of blood, which had dried. There were around 10 dogs in the house, poor hygienic and sanitary conditions, widespread excrements and unbreathable air. Testimonies from general practitioner, neighbors and the partner were collected. An autopsy, histological and toxicological examination was performed. On external examination the face showed blood smearing down the nose, subconjunctival hemorrhages, and labial cyanosis. Mo-reover, a hypochromic skin area was present on the right lateral region of the neck. The inguinal region showed large de-epithelized areas with multiple purplish red ecchymoses which were histologically analyzed. These areas showed hemorrhagic infiltration in the superficial and deep dermis up to the adipose tissue due to traumatic action.
CONCLUSION: The reconstruction of the case allowed us to state a strangulation probably attributable to a belt. The discovery of intradermal hemorrhagic infiltrations, supported by histopathological investigations, confirmed the diagnosis of blunt force injuries, excluding other type of non-violent causes of lesions. Therefore, we recommended the use of experimental methods and procedures to evaluate the harmful suitability on biological matrices.
Risk Summary 

XENOVIEW is minimally absorbed systemically following the inhalation route of administration, and maternal use is not expected to result in fetal exposure to the drug [see Clinical Pharmacology (12.3)]. Adequately designed animal reproduction studies have not been conducted with hyperpolarized xenon Xe 129. Although not adequately designed to evaluate reproductive and developmental toxicity, there are animal reproduction data available in the literature. Animal reproduction studies were conducted in rats by administering an 80% Xe/20% O2 gas mixture for 2 hours twice a week for 2 and 10 weeks, with no observed effects on fertility or pregnancy. Gas mixtures containing 70% to 75% Xe gas and 25% to 30% O2 gas were found to be non-teratogenic in rats when administered for 24 hours. In a separate study, rats were administered an 80%/20% Xe/O2 gas mixture for 2 hours twice a week from the first to nineteenth day of pregnancy with no observed effects on embryo-fetal development or signs of teratogenicity.

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively.
Immune checkpoint blockade has led to great strides in the management of various cancers, however, durable response could be seen in approximately 20% of treated patients with most solid malignancies. Immunosuppressive entities such as transforming growth factor-β (TGF-β) in the tumor microenvironment (TME) remain a major impediment. Enhancer of zeste homolog 2 (EZH2) is the core component of the polycomb group complex, which play a major role in cellular proliferation and differentiation. EZH2 aberration has been seen in a wide range of solid tumors and hematological malignancies, affecting tumor progression and immune cells in the tumor microenvironment, and it is associated with poor clinical prognosis and outcomes. EZH2 is not only an activator of gene expression through different pathways, but also a critical epigenetic repressor through histone methylation. Therefore, EZH2 has attracted significant interest as a potential epigenetic target for cancer treatment. It is hypothesized that the combination of EZH2 inhibitors and programmed death-1 ligands/ transforming growth factor-β (PD-L1/TGFβ) blockade could enhance the efficiency of immunotherapy.

The primary objective of this study in phase Ⅰstage is to assess the safety, feasibility of EZH2 inhibitor SHR2554 in combination with anti-PD-L1/TGFβ antibody SHR1701 in advanced pretreated solid tumors and b-cell lymphomas. The second objectives include characterizing the pharmacokinetics of SHR2554 in combination with SHR1701, evaluating the preliminary efficacy of SHR2554 plus SHR1701 and the epigenetic modulating effect of SHR2554 in its combination with anti-PD-L1/TGFβ antibody. The exploratory objectives are to evaluate the pathological, immunological or clinical predictive factors for efficacy and toxicity. Based on the data of safety, efficacy and recommended dose level obtained from phase Ⅰtrial, this study moves into phase Ⅱ stage, in which enrolled subjects are randomized to SHR2554 plus SHR 1701 or SHR1701 monotherapy, to primarily evaluate the efficacy of SHR2554 plus SHR1701 and the epigenetic modulating effect of SHR2554. The second objectives include evaluating safety and other efficacy parameters, such as overall response rate (ORR), disease control rate (DCR), duration of response (DOR) and overall survival (OS). The exploratory objectives are to evaluate laboratory predicting biomarkers.
FIELD: medicine. ^ SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to percutaneous drug delivery composition containing mixed steroid in therapeutically effective amount and relevant steroid derivative. In the preferential version said mixture contains pharmaceutically active agent in therapeutically effective amount containing steroid and steroid derivative, and also a pharmaceutical carrier. Steroid and relevant steroid derivative are taken in mass ratio 10:1 to 1:10 steroid/relevant steroid derivative. In the preferential version said ratio is 6:1 to 1:6. In the preferential version relevant steroid derivative is steroid ester. In the other version the carrier is polymer containing a press-sensitive adhesive. In another version a parent drug is ACE inhibitor, such as Ramipril, and a prodrug is ACE inhibitor prodrug, such as ethyl ester of Ramipril and/or methyl ester of Ramipril. ^ EFFECT: composition characterised with lower crystallisation in system possesses advanced steroid flow rate. ^ 34 cl, 10 ex, 7 dwg, 3 tbl
The invention discloses a pharmaceutical composition for nourishing yin and tonifying kidney. The pharmaceutical composition is characterized by being composed of the following raw materials: American ginseng, astragali, prepared rehmannia root, pulp of dogwood fruit, fleece-flower root, dried Chinese yam, alisma rhizome, tree peony bark, tuckahoe, phellodendron, licorice and hemlock parsley. The pharmaceutical composition is mainly used for nourishing yin and tonifying kidney, reducing pathogenic fire and nourishing liver, and eliminating dampness and alleviating pain. The modern application is that the pharmaceutical composition is applied to the patients suffering from deficiency of qi and yin. The pharmaceutical composition is mainly used for patients suffering from chronic nephritis, hypertension, diabetes, phthisis, nephrotuberculosis, hyperthyroidism, optic neuritis, cataract, central retinitis, non-ovulatory metropathia hemorrhagica, menopause syndrome, cervical vertebra and lumbar vertebra diseases, anemia, chronic prostatitis and other syndromes with deficiency of the kidney-yin as main pathogenesis. Modern research shows that nervous centralis is effectively reinforced, the purposes of eliminating fatigue, enhancing memory, improving insomnia and dysphoria, senile dementia and other symptoms, and has good curative effect on patients suffering from dismayed and short breath and cardiovascular diseases. The pharmaceutical composition can also be used for inhibiting thrombocyte aggregation, reducing blood coagulation property, lowering blood sugar and improving body immunity.
The invention relates to medicinal liquor for curing liver diseases, particularly to medicinal liquor for curing swelling and pain of liver. From a traditional Chinese medicine perspective, the pathology of the swelling and pain of liver is caused by nothing more than Qi stagnation, blood stasis and damp-heat accumulation. Of course, poor nourishment of liver and deficiency of liver and kidney are also included. The medicinal liquor has nursing and recuperating effects on people who have liver depression and swelling and pain of liver, and can achieve effects of relieving liver for smooth Qi, removing blood stasis and promoting blood circulation, breaking stagnation and relieving pain, dissipating dampness and clearing heat, and nourishing kidney and liver. Rice wine is used for soaking traditional Chinese medicine to cure liver depression and swelling and pain of liver. Nine traditional Chinese medicines including radix paeoniae alba, radix paeoniae rubra, polygonum cuspidatum, Chinese angelica root, licorice and the like are wrapped through gauze according to the specified amount of the formula and then placed into a container with a specified amount of 35% (70 proof) of rice wine for sealing and soaking for half a mouth, and then the medicinal liquor can be drank.
FIELD: organic chemistry, biochemistry. SUBSTANCE: invention describes an inhibitor of testosterone 5α-reductase of the molecular formula (I) 5α where dotted line means optional pi-bond; 5α means hydrogen atom or methyl-group but if the indicated optional bond is absent then it does not mean hydrogen atom;   means hydrogen atom; R 4  means hydrogen atom; R 6  means hydrogen atom or lower alkyl and R 7  means R 17α -alkyl or aryl tertiary amino-group or R 17β -alkyl or aryl amido-group. New compounds can be used for treatment of patients with androgen-sensitive diseases course of that can be delayed by inhibition of androgenic receptors activation. Invention describes also a composition based on compounds of the formula (I) and a method of inhibition of activity of testosterone C 1 -C 7 -reductase. EFFECT: valuable curative properties of compounds. 8 cl, 8 dwg, 8 tbl, 19 ex
The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme. The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme. Methods and apparatus for determining fluid characteristics are disclosed herein. An example apparatus includes a housing including an electrically insulating pane thermally insulated from the housing. The pane has an exterior surface to be disposed in a fluid and an interior surface to be isolated from the fluid. The example apparatus further includes a sensor including an electrical resistor coupled directly to the interior surface of the pane. The electrical resistor has an electrical resistance corresponding to a temperature of the electrical resistor.
PURPOSE: This study aimed to assess grating visual acuity and functional vision in children with congenital Zika syndrome.
METHODS: Initial and final grating visual acuity was measured using Teller acuity cards. Cerebral vision impairment standardized tests were used to assess functional vision. Patients were referred to the early visual intervention program for visually disabled children. Neuroimaging was performed.
RESULTS: In this study, 10 children were included with an age range of 1-37 months. Eight patients presented with macular atrophic scars. Neuroimaging revealed microcephaly and cerebral abnormalities in all patients. Low vision and cerebral vision impairment characteristics were observed in all children. The final grating visual acuity in this group varied from 3.00 to 0.81 logMAR.
CONCLUSIONS: The grating visual acuity test revealed low vision in all children with congenital Zika syndrome. Functional vision evaluation revealed cerebral vision impairment characteristics in all patients, who were referred to the early visual intervention program. Visual acuity improved in six children.
Vandetanib was not carcinogenic in a 2-year study in rats when administered by daily oral gavage at doses of up to 10 mg/kg (0.7 times the human Cmax at the 300 mg clinical dose), or in the Tg∙RasH2 mouse when administered by daily oral gavage at doses of up to 30 mg/kg (~5 times the human Cmax at the clinical dose of 300 mg) for 26 weeks. Vandetanib was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay and was not clastogenic in either the in vitro cytogenetic assay using human lymphocytes or in the in vivo rat micronucleus assay.

Based on nonclinical findings, male and female fertility may be impaired by treatment with CAPRELSA. In a fertility study of male rats, vandetanib had no effect on copulation or fertility rate when untreated females were mated with males administered 1, 5, or 20 mg/kg/day of vandetanib (approximately 0.03, 0.22, or 0.40 times, respectively, the human exposure based on area under the curve (AUC) in patients with cancer at the 300 mg clinical dose); however, in the same study there was a slight decrease in the number of live embryos in females mated with males treated at the 20 mg/kg/day dose level and an increase in preimplantation loss in females mated with males administered vandetanib at doses of ≥5 mg/kg/day. In a female fertility study, there was a trend towards increased estrus cycle irregularity, a slight reduction in pregnancy incidence and an increase in implantation loss. In a one-month repeat-dose toxicity study in rats, there was a decrease in the number of corpora lutea in the ovaries of rats administered 75 mg/kg/day vandetanib (approximately 1.8 times the human exposure based on AUC at the 300 mg clinical dose).